New research from Mayo Clinic is adding more fuel to the idea that a simple blood test could someday spot Alzheimer’s risk long before memory problems show up. The study focused on a brain-related protein tied to the disease and found that it may help estimate who is more likely to slide into cognitive decline over the next several years.
The work centered on phosphorylated tau 217, better known as p-tau217, in 2,178 adults who were cognitively unimpaired and between 60 and 90 years old. Researchers also factored in age, sex, and whether a person carried the APOE ε4 genetic variant, a well-known risk factor for Alzheimer’s.
Those participants came from the Mayo Clinic Study of Aging and the Alzheimer’s Disease Neuroimaging Initiative, where they went through blood biomarker testing, genetic testing, and repeated cognitive checks. That mix gave the team a detailed look at how a blood marker might line up with later changes in brain health.
One of the striking takeaways was that age still mattered a lot, even after the blood marker was taken into account. APOE ε4 showed only a modest added link to risk once p-tau217 was included, while older age continued to push the odds higher.
The numbers tell the story in a pretty blunt way. At the same elevated p-tau217 level, a 65-year-old had an estimated 6% five-year risk of mild cognitive impairment, while the risk jumped to 37% for an 85-year-old.
That kind of difference is exactly why researchers are excited about blood-based screening. Alzheimer’s disease is tied to plaques and tangles building up in the brain, and Clifford Jack Jr., a Mayo Clinic neuroradiologist and senior author of the study, said the test can reveal whether that pathology is present just from a blood sample.
He also pointed out that higher levels of that pathology are linked with a greater chance of moving from normal cognition to impairment. In plain terms, the blood test may not just flag a disease process, it may help show how dangerous that process could be over time.
The appeal is obvious because the test is far easier to use than PET scans, which are expensive and much less accessible. The researchers said blood testing could be a less invasive and more scalable way to estimate amyloid burden, another hallmark of Alzheimer’s that is tied to later cognitive problems.
Alicia Algeciras-Schimnich, a Mayo Clinic laboratory medicine and pathology researcher and the study’s first author, said the bigger goal is not just getting a positive or negative result. The aim is to give patients a more personal estimate of future risk that is actually useful in a real conversation with a clinician.
That future may matter even more if treatments that slow or prevent decline keep advancing. Jack said that if preventive options become available, this kind of information could help doctors and patients weigh the possible benefits and downsides of treatment in a more informed way.
Still, the study comes with some hard limits. The risk model was built from a population in southeast Minnesota, and Jack noted that this group does not mirror the entire United States, so the results need to be repeated in other places before anyone gets too carried away.
The team also stressed that the test is not ready for routine use in people who have no symptoms. Jack said there is currently no approved treatment for people who have Alzheimer’s pathology in the brain but are still asymptomatic, so in that setting, the result would not change medical care.
That could shift if new preventive therapies prove effective and win approval. For now, the more cautious reading is that the test may be a promising way to estimate risk, not a cure, and not a shortcut to better outcomes.
Even with its promise, the research also reminds doctors and families that Alzheimer’s biology does not always turn into visible illness. Some older adults carry the pathology at lower levels and never develop symptoms during their lifetime, while others may die of something else before memory loss ever appears.
